Price 6 Months Forecast & Ratings

Sign up to access Target Price

Sign up

AI Score



Sign up to see AI score

Brand Score 90
Employment Score 47
User Growth Score 17
Fundamental Score 54

What is the target price for Recursion Pharmaceuticals?

On November 22, an AI target price of Premium - Sign up was allocated to Recursion Pharmaceuticals (RXRX). This projected target price was predicated on several factors, including a month over month spike in Twitter followers, a month over month spike in job posts, an encouraging high business outlook across the company's employees, year over year increase in revenue, and a month over month spike in Youtube subscribers.

Is RXRX a Buy, Sell or Hold?

Based on Alternative Data, Recursion Pharmaceuticals is a hold.

Should I buy RXRX stock?

Alternative data suggests that it's recommended to approach Recursion Pharmaceuticals (RXRX) with caution. While there are positive indicators, the overall assessment suggests a hold based on Alternative Data analysis. However, this information should not be considered financial advice.

What Is the RXRX Stock Forecast for 2025?

With an AI score of 51, the RXRX stock forecast suggests stability.

What is the RXRX price prediction for 2025?

To predict the price for RXRX in 2025, we can extrapolate the AI price target. This approach projects RXRX's price to reach $5.75.

What is the RXRX price prediction for 2030?

To predict the price for RXRX in 2030, we can again extrapolate the AI price target. This approach projects RXRX's price to reach $7.25.

How do we predict the price for RXRX?

When predicting the price for RXRX, our approach incorporates multiple scores assessing different aspects of the company. The Brand score measures growth and engagement across social media channels, indicating audience reach. The Employee score evaluates workforce health, considering job postings, business outlook, and employee ratings. The Customer score examines engagement on websites, app downloads, and sentiment in stock forums. Lastly, the Fundamental score analyzes financial statements and analyst ratings. By evaluating this data, we gain a holistic view of the company's performance, enabling more informed price predictions.

Will RXRX go up tomorrow?

Based on technical analysis of how the price has moved over the last 6 months is hard to tell since there has been no significant change in the price today to base a prediction on.
Note that this is a simplistic analysis and should be used with caution, as prices are influenced by a myriad of factors.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.